Comparing Dose-response Profiles of Uterotonics After Initial Carbetocin Administration in Human Uterine Tissue

What this Trial Is About

Researchers are investigating how different uterotonic drugs affect the contraction of the uterus after a cesarean delivery, especially when the first dose of carbetocin has been given. Uterine contraction is crucial to prevent postpartum hemorrhage caused by uterine atony, a condition where the uterus does not contract properly leading to excessive bleeding. This study aims to find which uterotonic drug—oxytocin, carbetocin, ergometrine, or carboprost—is most effective at enhancing uterine contraction after initial carbetocin use by testing tissue samples taken from the uterus. The study uses small samples of uterine muscle tissue collected from the incision site during cesarean section and exposes these samples to carbetocin followed by other uterotonic drugs. Researchers will test increasing doses of carbetocin, oxytocin, ergometrine, and carboprost in the laboratory to see how each affects uterine contraction. A control group with no drug added will also be included. This ex-vivo testing helps compare the effects of these drugs on tissue that has been previously treated with carbetocin. Participants are women undergoing elective cesarean delivery between 37 and 41 weeks of gestation who have not been exposed to oxytocin during labor. Tissue samples will be collected during surgery, and contractions will be measured by motility index, contraction amplitude, frequency, and response curves over four hours. The study will evaluate how well second doses of uterotonics improve contraction in desensitized uterine tissue. Safety monitoring and follow-up are managed within the surgical setting, and the study is expected to complete by December 2026.

Comparing the Dose-response Profiles of Uterotonics After Initial Carbetocin Administration - an Ex-vivo Study in Desensitized Human Myometrium